Abstract | PURPOSE: METHODS: We studied the metabolism of and tolerance to mercaptopurine in murine knockout models of Tpmt, Mrp4, and both genes simultaneously. RESULTS: Upon mercaptopurine treatment, Tpmt -/- Mrp4 -/- mice had the highest concentration of bone marrow thioguanine nucleotides (8.5 pmol/5 × 106 cells, P = 7.8 × 10-4 compared with 2.7 pmol/5 × 106 cells in wild-types), followed by those with Mrp4 or Tpmt deficiency alone (6.1 and 4.3 pmol/5 × 106 cells, respectively). Mrp4-deficient mice accumulated higher concentrations of methylmercaptopurine metabolites compared with wild-type (76.5 vs. 23.2 pmol/5 × 106 cells, P = 0.027). Mice exposed to a clinically relevant mercaptopurine dosing regimen displayed differences in toxicity and survival among the genotypes. The double knock-out of both genes experienced greater toxicity and shorter survival compared to the single knockout of either Tpmt (P = 1.7 × 10-6) or Mrp4 (P = 7.4 × 10-10). CONCLUSIONS: We showed that both Tpmt and Mrp4 influence mercaptopurine disposition and toxicity.
|
Authors | Chengcheng Liu, Laura J Janke, Jun J Yang, William E Evans, John D Schuetz, Mary V Relling |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 80
Issue 2
Pg. 287-293
(Aug 2017)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 28623449
(Publication Type: Journal Article)
|
Chemical References |
- Abcc4 protein, mouse
- Antimetabolites, Antineoplastic
- Multidrug Resistance-Associated Proteins
- 6-methylthiopurine
- Mercaptopurine
- Methyltransferases
- thiopurine methyltransferase
|
Topics |
- Animals
- Antimetabolites, Antineoplastic
(administration & dosage, pharmacokinetics, toxicity)
- Female
- Genotype
- Male
- Mercaptopurine
(administration & dosage, analogs & derivatives, metabolism, pharmacokinetics, toxicity)
- Methyltransferases
(genetics)
- Mice, Knockout
- Multidrug Resistance-Associated Proteins
(genetics)
|